<DOC>
	<DOC>NCT00996203</DOC>
	<brief_summary>This open-label single arm study will evaluate the efficacy and safety of tocilizumab added to traditional disease-modifying antirheumatic drugs (DMARDs) in patients with moderate to severe active rheumatoid arthritis and an inadequate response to DMARDs. Patients will receive tocilizumab 8 mg/kg by intravenous infusion every 4 weeks for 24 weeks, in addition to their current non-biologic DMARDs at stable doses. Anticipated time on study treatment is 24 weeks, and the target sample size is 200.</brief_summary>
	<brief_title>A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>adult patients, &gt;/= 18 years of age moderate to severe active rheumatoid arthritis of &gt;/=6 months duration inadequate clinical response to current nonbiologic DMARDs current DMARDs must be at stable dose for 8 weeks prior to study entry oral corticosteroids (&lt;/=10mg/day prednisone or equivalent) and NSAIDs must be at stable dose for &gt;/=4 weeks prior to screening rheumatic autoimmune disease other than RA history of or current inflammatory joint disease other than RA previous treatment with any biologic DMARD functional class IV as defined by the ACR classification intraarticular or parenteral corticosteroids within 6 weeks prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>